The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
Study sponsor: Okyo Pharma Ltd · OKYO
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-12-15Actual
Enrollment · participants240Actual
Source updated2024-02-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.